The Global Pharmacogenomics Market was valued at US$ 5.58 Billion in 2024 and is expected to grow at a CAGR of 10.6% from 2024 to 2034. In 2024, North America led the market, achieving over 48.5% share with a revenue of US$ 2.7 Billion.

In 2025, the Pharmacogenomics Market is entering a transformative era as precision prescribing becomes central to oncology and cardiovascular treatment. Genomic profiling panels are now routinely ordered before chemotherapy or clopidogrel prescribing, helping clinicians avoid ineffective regimens or adverse drug reactions. Health systems are integrating pharmacogenomic alerts into EHRs so that when a drug is ordered, the system cross-checks the patient’s genotype and suggests tailored dosages or alternatives. This has led to a 30% reduction in adverse events and improved therapeutic success rates.

Payers are now incentivizing genetic testing through aalue-based contracts, supporting upfront genotyping to prevent downstream complications. As healthcare pivots toward safer and smarter prescribing, pharmacogenomics is moving from niche applications to standard of care—empowering providers to deliver personalized medicine guided by each patient’s DNA.

Click here for more information: https://market.us/report/pharmacogenomics-market/

Key Takeaways

• • The Pharmacogenomics market generated a revenue of US$ 5.6 Billion and is predicted to reach US$ 15.3 Billion, with a CAGR of 10.6%.
  • Based on the Technology, the Polymerase Chain Reaction segment generated the most revenue for the market with a market share of 45.9%.
  • Based on the application, the Oncology segment generated the most revenue for the market with a market share of 35.2%.
  • Based on the End-User, the Hospital & Clinics segment generated the most revenue for the market with a market share of 48.7%.
  • Region-wise, North America remained the lead contributor to the market, by claiming the highest market share, amounting to 48.5%.

Key Market Segments

By Technology

• • Sequencing
  • Microarray
  • Polymerase Chain Reaction
  • Others

By Application

• • Drug Discovery
  • Infectious Diseases
  • Oncology
  • Cardiovascular Diseases
  • Other Applications

By End-User

• • Hospital & Clinics
  • Research Organizations
  • Others

Emerging Trends

1. 1. Pharmacogenomic alerts embedded in EHR medication workflows.
   2. Oncology genotyping panels guiding chemotherapy drug choice.
   3. Cardiovascular genotyping (e.g., CYP2C19) driving antiplatelet dosing decisions.
   4. Value-based payer incentives for upfront pharmacogenomic testing.

Use Cases

1. 1. Oncologists reference a tumor genomics panel to select non-toxic targeted agents.
   2. A cardiac patient’s CYP2C19 variant prompts switch from clopidogrel to ticagrelor.
   3. Genotyping informs dosing of antidepressant medications to avoid toxicity.
   4. Health plan waives testing copays for high-risk medications to improve adherence.